Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
Clinical trial NCT07340398 · RECRUITING
Trial details
- NCT number
- NCT07340398
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-25
- Primary completion
- 2028-12-31
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.